Shares of Atara Biotherapeutics (NASDAQ:ATRA) continued to trade lower in the premarket on Tuesday after the U.S. Food and Drug Administration (FDA) slapped the cell therapy developer with a ...

In February, Atara Biotherapeutics paused enrolment into a trial of a CAR-T cell therapy for mesothelioma after a patient death. Now, its partner Bayer has backed out of a partnership covering two ...

Atara's CEO, Cokey Nguyen, Ph.D., expressed confidence in eventually obtaining marketing approval for EBVALLO and filing for a resubmission, which could potentially be approved within six months ...